Products - Pulmonary fibrosis | Topic | NICE

Showing 7 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted (TA864)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2023
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 November 2021
Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 February 2018
Nintedanib for treating idiopathic pulmonary fibrosis (TA379)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 January 2016
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC